The record
| Class | hormone |
|---|---|
| Also known as | Salcatonin, Miacalcin, Fortical, sCT |
| Chain length | - |
| Molecular weight | 3,431.9 Da |
| Half-life | 43-64 minutes (SC/IM); ~18 minutes (intranasal) |
| Route | Intranasal (spray) / SC / IM / IV |
| Studied for | Postmenopausal osteoporosis (5+ years post-menopause); Paget's disease of bone; Hypercalcemia (emergency treatment); Bone pain from metastases |
| Research use | Bone metabolism studies; Osteoclast biology; Calcium homeostasis research |
| What has been shown | Reduces new vertebral fractures; Increases lumbar spine BMD; Rapidly lowers serum calcium in hypercalcemia; Analgesic effect on bone pain |
| How it works | 32-amino acid peptide hormone that binds to calcitonin receptors (CALCR), activating cAMP-dependent pathways. Inhibits osteoclast activity (bone resorption) and increases renal excretion of calcium, phosphate, sodium, magnesium. Salmon calcitonin has 40-50x greater potency than human calcitonin due to higher receptor affinity and resistance to degradation. |
| Patent status | expired |
| Regulatory status | FDA approved (Miacalcin, Fortical) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Bone Health / Remodeling Support (affection, 43%)
- Bone pain from metastases (illness, 100%)
- Glucocorticoid-induced osteoporosis (illness, 60%)
- Hypercalcemia (illness, 100%)
- Male osteoporosis (illness, 60%)
- Paget's disease of bone (illness, 100%)
- Postmenopausal osteoporosis (illness, 100%)
- Pain (symptom, 50%)